IDEAYA Biosciences, Inc. (IDYA)
26.54
+0.37
(+1.41%)
USD |
NASDAQ |
Nov 20, 10:10
IDEAYA Biosciences Cash from Operations (Quarterly) : -93.48M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -93.48M |
| June 30, 2026 | -88.21M |
| March 31, 2026 | -75.17M |
| December 31, 2025 | -90.50M |
| September 30, 2025 | 142.21M |
| June 30, 2025 | -62.47M |
| March 31, 2025 | -60.34M |
| December 31, 2024 | -121.66M |
| September 30, 2024 | -49.23M |
| June 30, 2024 | -32.88M |
| March 31, 2024 | -43.81M |
| December 31, 2023 | -23.75M |
| September 30, 2023 | -30.17M |
| June 30, 2023 | -33.46M |
| March 31, 2023 | -27.84M |
| December 31, 2022 | -23.37M |
| September 30, 2022 | -24.17M |
| June 30, 2022 | -19.99M |
| Date | Value |
|---|---|
| March 31, 2022 | -19.65M |
| December 31, 2021 | -16.66M |
| September 30, 2021 | -12.47M |
| June 30, 2021 | -12.93M |
| March 31, 2021 | -13.72M |
| December 31, 2020 | -11.60M |
| September 30, 2020 | 90.21M |
| June 30, 2020 | -13.61M |
| March 31, 2020 | -9.545M |
| December 31, 2019 | -8.706M |
| September 30, 2019 | -10.55M |
| June 30, 2019 | -10.27M |
| March 31, 2019 | -9.785M |
| December 31, 2018 | -7.477M |
| September 30, 2018 | -8.691M |
| June 30, 2018 | -5.926M |
| March 31, 2018 | -5.526M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Ironwood Pharmaceuticals, Inc. | 67.40M |
| Xencor, Inc. | 2.642M |
| ACADIA Pharmaceuticals, Inc. | 11.50M |
| Arrowhead Pharmaceuticals, Inc. | -192.40M |
| BioMarin Pharmaceutical, Inc. | 188.21M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 78.65M |
| Cash from Financing (Quarterly) | 3.695M |
| Free Cash Flow | -349.80M |
| Free Cash Flow Per Share (Quarterly) | -0.9107 |
| Free Cash Flow to Equity (Quarterly) | -94.15M |
| Free Cash Flow to Firm (Quarterly) | -93.75M |
| Free Cash Flow Yield | -13.64% |